Sabine Irtan
Outcomes of non-anaplastic stage III and ‘inoperable’ Wilms tumour treated in the UKW3 trial
Irtan, Sabine; Messahel, Boo; Moroz, Veronica; Taylor, Roger E.; Grundy, Richard; Kelsey, Anna; Vujanic, Gordan; Pritchard-Jones, Kathy
Authors
Boo Messahel
Veronica Moroz
Roger E. Taylor
RICHARD GRUNDY richard.grundy@nottingham.ac.uk
Professor of Paediatric Neuro-Oncology
Anna Kelsey
Gordan Vujanic
Kathy Pritchard-Jones
Abstract
© 2018 Background and purpose: To describe the outcome of patients with stage III Wilms tumours (WT) treated in the UKW3 trial. Material and methods: Patients with a pathologically confirmed stage III non-anaplastic WT at nephrectomy (Group A) or with an ‘inoperable’ tumour at diagnosis managed by biopsy and pre-operative chemotherapy (Actinomycin D-Vincristine-Doxorubicin) but stage I or II at subsequent nephrectomy (Group B) were included. Results: The 4-year overall (OS)/event free survival (EFS) for Group A (n = 117) patients was 90%(95%CI:83–94)/81%(CI:73–87) and for Group B (n = 32) 94%(CI:77–98)/88%(CI:70–95). The 4-year OS/EFS of patients with pathological stage III WT according to whether they received flank/abdominal radiotherapy (95 patients) or not (37 patients, 22 from UKW3 pooled with 17 patients from UKW2) were 91%(CI:83–95)/82%(CI:73–89), and 84%(CI:67–92)/78%(CI:61–89), respectively. The 4-year OS/EFS for patients having one reason to be stage III versus two or three was 92%(CI:84–96)/83%(CI:73–90) and 85%(CI:70–93)/78%(CI:61–88), respectively. Conclusion: Our findings question the inclusion of biopsy or pre-operative chemotherapy as sole criterion for assigning a tumour stage III. Selected patients with pathological stage III WT can survive without radiotherapy. Whilst cautious interpretation is needed due to the post hoc nature of these analyses, further biological studies may better characterise those who could benefit from reduced therapy.
Citation
Irtan, S., Messahel, B., Moroz, V., Taylor, R. E., Grundy, R., Kelsey, A., …Pritchard-Jones, K. (2019). Outcomes of non-anaplastic stage III and ‘inoperable’ Wilms tumour treated in the UKW3 trial. Radiotherapy and Oncology, 131, 1-7. https://doi.org/10.1016/j.radonc.2018.10.026
Journal Article Type | Article |
---|---|
Acceptance Date | Oct 23, 2018 |
Online Publication Date | Dec 15, 2018 |
Publication Date | Feb 1, 2019 |
Deposit Date | Jun 6, 2019 |
Publicly Available Date | Mar 29, 2024 |
Journal | Radiotherapy and Oncology |
Print ISSN | 0167-8140 |
Electronic ISSN | 1879-0887 |
Publisher | Elsevier |
Peer Reviewed | Peer Reviewed |
Volume | 131 |
Pages | 1-7 |
DOI | https://doi.org/10.1016/j.radonc.2018.10.026 |
Public URL | https://nottingham-repository.worktribe.com/output/2151250 |
Publisher URL | https://www.sciencedirect.com/science/article/pii/S0167814018335503 |
Additional Information | This article is maintained by: Elsevier; Article Title: Outcomes of non-anaplastic stage III and ‘inoperable’ Wilms tumour treated in the UKW3 trial; Journal Title: Radiotherapy and Oncology; CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.radonc.2018.10.026; Content Type: article; Copyright: © 2018 Published by Elsevier B.V. |
You might also like
Recurrent ACVR1 mutations in posterior fossa ependymoma
(2022)
Journal Article
Downloadable Citations
About Repository@Nottingham
Administrator e-mail: digital-library-support@nottingham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search